

Artificial Intelligence (AI) in Drug Discovery Market by Offering (Software, Service), Technology (Machine Learning, Deep Learning), Application (Cardiovascular, Metabolic, Neurodegenerative), End User (Pharma, Biotech,CROs) - Global Forecasts (2022 - 2027)

Market Report | 2022-06-15 | 193 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The Artificial intelligence/AI in drug discovery Market is projected to reach USD 4.0 billion by 2027 from USD 0.6 billion in 2022, at a CAGR of 45.7% during the forecast period. The growth of this market is primarily driven by factors such as the need to control drug discovery & development costs and reduce the overall time taken in this process, the rising adoption of cloud-based applications and services. On the other hand, the inadequate availability of skilled labor is key factor restraining the market growth at certain extent over the forecast period. .

"Services segment is estimated to hold the major share in 2022 and also expected to grow at the highest over the forecast period" On the basis of offering, the AI in drug discovery market is bifurcated into software and services. the services segment expected to account for the largest market share of the global AI in drug discovery services market in 2022, and expected to grow fastest CAGR during the forecast period. The advantages and benefits associated with these services and the strong demand for AI services among end users are the key factors for the growth of this segment.

"Machine learning technology segment accounted for the largest share of the global AI in drug discovery market"

On the basis of technology, the AI in drug discovery market is segmented into machine learning and other technologies. The machine learning segment accounted for the largest share of the global market in 2021 and expected to grow at the highest CAGR during the forecast period. High adoption of machine learning technology among CRO, pharmaceutical and biotechnology companies and capability of these technologies to extract insights from data sets, which helps accelerate the drug discovery process are some of the factors supporting the market growth of this segment.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

"Pharmaceutical & biotechnology companies segment expected to hold the largest share of the market in 2022"

On the basis of end user, the AI in drug discovery market is divided into pharmaceutical & biotechnology companies, CROs, and research centers and academic & government institutes. In 2021, the pharmaceutical & biotechnology companies segment accounted for the largest share of the AI in drug discovery market. On the other hand, research centers and academic & government institutes are expected to witness the highest CAGR during the forecast period. The strong demand for AI-based tools in making the entire drug discovery process more time and cost-efficient is the key growth factor of pharmaceutical and biotechnology end-user segment.

"North America to dominate the AI in drug discovery market in 2021"

The global AI in the drug discovery market is segmented into four major regions, namely, North America, Europe, APAC, and the Rest of the World. In 2021, North America accounted for the largest and the fastest-growing regional market for AI in drug discovery. North America, which comprises the US, Canada, and Mexico, forms the largest market for AI in drug discovery. These countries have been early adopters of AI technology in drug discovery and development. Presence of key established players, well-established pharmaceutical and biotechnology industry, and high focus on R&D & substantial investment are some of the major factors responsible for the large share and high growth rate of this market.

Breakdown of supply-side primary interviews, by company type, designation, and region:

- By Company Type: Tier 1 (31%), Tier 2 (28%), and Tier 3 (41%)
- By Designation: C-level (31%), Director-level (25%), and Others (44%)
- By Region: North America (45%), Europe (20%), Asia Pacific (28%), and RoW (7%)

Prominent players in this market are NVIDIA Corporation (US), Microsoft Corporation (US), Google (US), Exscientia (UK), Schrodinger (US), Atomwise, Inc. (US), BenevolentAI (UK), NuMedii (US), BERG LLC (US), Cloud Pharmaceuticals (US), Insilico Medicine (US), Cyclica (Canada), Deep Genomics (Canada), IBM (US), BIOAGE (US), Valo Health (US), Envisagenics (US), twoXAR (US), Owkin, Inc. (US), XtalPi (US), Verge Genomics (US), Biovista (US), Evaxion Biotech (Denmark), Iktos (France), Standigm (South Korea), and BenchSci (Canada). Players adopted organic as well as inorganic growth strategies such as product upgrades, collaborations, agreements, partnerships, and acquisitions to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Research Coverage

- The report studies the AI in drug discovery market based on offering, technology, application, end user, and region
- The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth
- The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders
- The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total AI in drug discovery market
- The report forecasts the revenue of market segments with respect to five major regions

□

Key Benefits of Buying the Report:

The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the AI in drug discovery market and provides them information on key market drivers, restraints, challenges, and opportunities.

Table of Contents:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1	INTRODUCTION	26
1.1	OBJECTIVES OF THE STUDY	26
1.2	MARKET DEFINITION	26
1.2.1	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: INCLUSIONS & EXCLUSIONS	27
1.3	MARKET SCOPE	28
1.3.1	MARKETS COVERED	28
	FIGURE 1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY: MARKET SEGMENTATION	28
1.3.2	YEARS CONSIDERED FOR THE STUDY	28
1.4	CURRENCY	29
1.5	LIMITATIONS	29
1.6	STAKEHOLDERS	29
1.7	SUMMARY OF CHANGES	30
2	RESEARCH METHODOLOGY	31
2.1	RESEARCH DATA	31
	FIGURE 2 RESEARCH DESIGN	31
2.2	SECONDARY SOURCES	32
2.2.1	KEY DATA FROM SECONDARY SOURCES	33
2.3	PRIMARY DATA	33
2.3.1	PRIMARY SOURCES	34
2.3.2	BREAKDOWN OF PRIMARY INTERVIEWS	35
	FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE, SUPPLY SIDE, DESIGNATION, AND REGION	35
2.3.2.1	Key industry insights	35
2.4	MARKET SIZE ESTIMATION	36
	FIGURE 4 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS	37
	FIGURE 5 BOTTOM-UP APPROACH: END-USER SPENDING ON AI IN DRUG DISCOVERY	38
	TABLE 1 FACTOR ANALYSIS	40
	FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE AI IN DRUG DISCOVERY MARKET (2022-2027)	40
	FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS	41
	FIGURE 8 TOP-DOWN APPROACH	41
2.5	MARKET BREAKDOWN AND DATA TRIANGULATION	42
	FIGURE 9 DATA TRIANGULATION METHODOLOGY	42
	TABLE 2 MARKET SIZING ASSUMPTIONS	43
2.6	OVERALL STUDY ASSUMPTIONS	43
2.7	LIMITATIONS	44
2.8	RISK ASSESSMENT	44
	TABLE 3 RISK ASSESSMENT: AI IN DRUG DISCOVERY MARKET	44
3	EXECUTIVE SUMMARY	45
	FIGURE 10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2022 VS. 2027 (USD MILLION)	45
	FIGURE 11 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)	46
	FIGURE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)	46
	FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET	47
4	PREMIUM INSIGHTS	48
4.1	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET OVERVIEW	48
	FIGURE 14 GROWING NEED TO CONTROL DRUG DISCOVERY & DEVELOPMENT COSTS IS A KEY FACTOR DRIVING THE ADOPTION OF AI IN DRUG DISCOVERY SOLUTIONS	48
4.2	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING (2021-2027)	49

FIGURE 15	SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD	49
4.3	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE & REGION (2021)	50
FIGURE 16	DEEP LEARNING SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2021	50
4.4	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	51
FIGURE 17	NORTH AMERICA IS THE FASTEST-GROWING REGIONAL MARKET FOR AI IN DRUG DISCOVERY	51
5	MARKET OVERVIEW	52
5.1	INTRODUCTION	52
5.2	MARKET DYNAMICS	52
FIGURE 18	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	52
5.2.1	MARKET DRIVERS	53
5.2.1.1	Growing number of cross-industry collaborations and partnerships	53
TABLE 4	INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS (2019-2021)	53
5.2.1.2	Growing need to control drug discovery & development costs and reduce time involved in drug development	54
5.2.1.3	Patent expiry of several drugs	54
TABLE 5	INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2022	54
5.2.2	MARKET RESTRAINTS	55
5.2.2.1	Shortage of AI workforce and ambiguous regulatory guidelines for medical software	55
5.2.3	MARKET OPPORTUNITIES	55
5.2.3.1	Growing biotechnology industry	55
5.2.3.2	Emerging markets	56
5.2.3.3	Focus on developing human-aware AI systems	56
5.2.3.4	Growth in the drugs and biologics market despite the COVID-19 pandemic	56
5.2.4	MARKET CHALLENGES	56
5.2.4.1	Limited availability of data sets	56
5.3	VALUE CHAIN ANALYSIS	57
FIGURE 19	AI IN DRUG DISCOVERY MARKET: VALUE CHAIN ANALYSIS (2021)	57
5.4	PORTER'S FIVE FORCES ANALYSIS	58
TABLE 6	AI IN DRUG DISCOVERY MARKET: PORTER'S FIVE FORCES ANALYSIS	58
5.5	ECOSYSTEM	59
FIGURE 20	AI IN DRUG DISCOVERY MARKET ECOSYSTEM	59
5.6	TECHNOLOGY ANALYSIS	59
5.7	PRICING ANALYSIS	60
5.8	BUSINESS MODELS	60
FIGURE 21	AI IN LIFE SCIENCES: BUSINESS MODELS	61
FIGURE 22	BENEFITS OF HYBRID BUSINESS MODELS	61
FIGURE 23	SPECIALIZATION OF AI COMPANIES OVER TIME	62
5.9	REGULATIONS	63
5.10	CONFERENCES AND WEBINARS	63
5.11	CASE STUDY ANALYSIS	64
5.11.1	CASE STUDY 1	64
5.11.2	CASE STUDY 2	65
6	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING	66
6.1	INTRODUCTION	67
TABLE 7	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)	67
6.2	SOFTWARE	67
6.2.1	BENEFITS OFFERED BY SOFTWARE IN DRUG DISCOVERY & STRONG DEMAND AMONG END USERS ARE DRIVING SEGMENT GROWTH	67

TABLE 8	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY REGION, 2020-2027 (USD MILLION)	68
TABLE 9	NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020-2027 (USD MILLION)	68
TABLE 10	EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020-2027 (USD MILLION)	68
TABLE 11	APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020-2027 (USD MILLION)	69
6.3	SERVICES	69
6.3.1	SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD	69
TABLE 12	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY REGION, 2020-2027 (USD MILLION)	70
TABLE 13	NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)	70
TABLE 14	EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)	70
TABLE 15	APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020-2027 (USD MILLION)	71
7	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY	72
7.1	INTRODUCTION	73
TABLE 16	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	73
7.2	MACHINE LEARNING	73
TABLE 17	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2020-2027 (USD MILLION)	74
TABLE 18	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY REGION, 2020-2027 (USD MILLION)	74
TABLE 19	NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)	74
TABLE 20	EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)	75
TABLE 21	APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)	75
7.2.1	DEEP LEARNING	75
7.2.1.1	Deep learning accelerates the discovery process of life-saving drugs and precision medicine	75
TABLE 22	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY REGION, 2020-2027 (USD MILLION)	76
TABLE 23	NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)	76
TABLE 24	EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)	77
TABLE 25	APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)	77
7.2.2	SUPERVISED LEARNING	77
7.2.2.1	Supervised learning can be applied in drug repositioning	77
TABLE 26	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY REGION, 2020-2027 (USD MILLION)	78
TABLE 27	NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)	78
TABLE 28	EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020-2027 (USD MILLION)	78
TABLE 29	APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020-2027	

(USD MILLION) 79

7.2.3 REINFORCEMENT LEARNING 79

7.2.3.1 Insilico Medicine is a pioneer in the application of reinforcement learning in drug discovery 79

TABLE 30 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2020-2027 (USD MILLION) 79

TABLE 31 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020-2027 (USD MILLION) 80

TABLE 32 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020-2027 (USD MILLION) 80

TABLE 33 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020-2027 (USD MILLION) 80

7.2.4 UNSUPERVISED LEARNING 81

7.2.4.1 Unsupervised learning can be more unpredictable than alternate models 81

TABLE 34 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2020-2027 (USD MILLION) 81

TABLE 35 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020-2027 (USD MILLION) 81

TABLE 36 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020-2027 (USD MILLION) 82

TABLE 37 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020-2027 (USD MILLION) 82

7.2.5 OTHER MACHINE LEARNING TECHNOLOGIES 82

TABLE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY REGION, 2020-2027 (USD MILLION) 83

TABLE 39 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020-2027 (USD MILLION) 83

TABLE 40 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020-2027 (USD MILLION) 83

TABLE 41 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020-2027 (USD MILLION) 84

7.3 OTHER TECHNOLOGIES 84

TABLE 42 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020-2027 (USD MILLION) 85

TABLE 43 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020-2027 (USD MILLION) 85

TABLE 44 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020-2027 (USD MILLION) 85

TABLE 45 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020-2027 (USD MILLION) 86

8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION 87

8.1 INTRODUCTION 88

TABLE 46 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 88

8.2 IMMUNO-ONCOLOGY 88

8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE SEGMENT GROWTH 88

TABLE 47 INDICATIVE LIST OF INITIATIVES IN IMMUNO-ONCOLOGY DRUG DEVELOPMENT 89

TABLE 48 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY REGION, 2020-2027 (USD MILLION) 89

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 49	NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)	89
TABLE 50	EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)	90
TABLE 51	APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)	90
8.3	NEURODEGENERATIVE DISEASES	90
8.3.1	AI IS BEING USED TO RESOLVE EXISTING CHALLENGES IN NEUROLOGICAL DISEASE DRUG DEVELOPMENT	90
TABLE 52	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2020-2027 (USD MILLION)	91
TABLE 53	NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)	91
TABLE 54	EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)	92
TABLE 55	APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)	92
8.4	CARDIOVASCULAR DISEASES	92
8.4.1	RIISING DEMAND FOR CVD DRUGS IS DRIVING SEGMENT GROWTH	92
TABLE 56	INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT	93
TABLE 57	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020-2027 (USD MILLION)	93
TABLE 58	NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)	93
TABLE 59	EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)	94
TABLE 60	APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)	94
8.5	METABOLIC DISEASES	94
8.5.1	ROLE OF AI IN UNCOVERING SMALL-MOLECULE THERAPIES IS DRIVING ITS ADOPTION IN THIS SEGMENT	94
TABLE 61	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY REGION, 2020-2027 (USD MILLION)	95
TABLE 62	NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)	95
TABLE 63	EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)	95
TABLE 64	APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)	96
8.6	OTHER APPLICATIONS	96
TABLE 65	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)	96
TABLE 66	NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)	97
TABLE 67	EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)	97
TABLE 68	APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)	97
9	ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER	98

9.1 INTRODUCTION 99

TABLE 69 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION) 99

9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 99

9.2.1 RISING DEMAND FOR SOLUTIONS TO CUT TIME AND COSTS OF DRUG DEVELOPMENT HAS DRAWN END-USER ATTENTION TO AI 99

TABLE 70 INDICATIVE LIST OF DEVELOPMENTS RELATED TO THE USE OF AI IN THE PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY 100

TABLE 71 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020-2027 (USD MILLION) 100

TABLE 72 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION) 101

TABLE 73 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION) 101

TABLE 74 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION) 101

9.3 CONTRACT RESEARCH ORGANIZATIONS 102

9.3.1 GROWING TREND OF OUTSOURCING TO PROVIDE SIGNIFICANT OPPORTUNITIES FOR CONTRACT RESEARCH ORGANIZATIONS 102

TABLE 75 INDICATIVE LIST OF COLLABORATIONS WITH CROs 102

TABLE 76 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020-2027 (USD MILLION) 102

TABLE 77 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION) 103

TABLE 78 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION) 103

TABLE 79 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION) 103

9.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES 104

9.4.1 THIS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 104

TABLE 80 INDICATIVE LIST OF RESEARCH COLLABORATIONS 104

TABLE 81 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2020-2027 (USD MILLION) 104

TABLE 82 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION) 105

TABLE 83 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION) 105

TABLE 84 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION) 105

10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION 106

10.1 INTRODUCTION 107

TABLE 85 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2020-2027 (USD MILLION) 107

10.2 NORTH AMERICA 107

FIGURE 24 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT 108

TABLE 86 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 109

TABLE 87 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION) 109

TABLE 88 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 109

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 89	NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	110
TABLE 90	NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)	110
10.2.1	US	110
10.2.1.1	Strong economy and trend of early adoption of technologies are driving market growth in the US	110
TABLE 91	INDICATIVE LIST OF STRATEGIC DEVELOPMENTS IN THE US MARKET	111
TABLE 92	US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)	111
TABLE 93	US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	112
TABLE 94	US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	112
TABLE 95	US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)	112
10.2.2	CANADA	113
10.2.2.1	Growing research on AI technologies and emergence of new AI-based start-ups will support market growth in Canada	113
TABLE 96	CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)	113
TABLE 97	CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	114
TABLE 98	CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	114
TABLE 99	CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)	114
10.2.3	MEXICO	115
10.2.3.1	Government initiatives to support market growth in Mexico	115
TABLE 100	MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)	115
TABLE 101	MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	115
TABLE 102	MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	116
TABLE 103	MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)	116
10.3	EUROPE	116
FIGURE 25	EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT	117
TABLE 104	EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	118
TABLE 105	EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)	118
TABLE 106	EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	118
TABLE 107	EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	119
TABLE 108	EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)	119
10.3.1	UK	119
10.3.1.1	UK holds the largest share of the European market	119
TABLE 109	INDICATIVE LIST OF STRATEGIC DEVELOPMENTS IN THE UK	120
TABLE 110	UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)	120
TABLE 111	UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	121
TABLE 112	UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	121
TABLE 113	UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)	121
10.3.2	GERMANY	122
10.3.2.1	Government support and favorable training programs are key market drivers in Germany	122
TABLE 114	GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)	122
TABLE 115	GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	123
TABLE 116	GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	123
TABLE 117	GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)	123
10.3.3	FRANCE	124
10.3.3.1	Strong government support and favorable strategies & initiatives to drive market growth in France	124
TABLE 118	FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)	124
TABLE 119	FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	124
TABLE 120	FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	125

TABLE 121	FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)	125
10.3.4	ITALY	125
10.3.4.1	Presence of a strong pharmaceutical industry in Italy to drive market growth	125
TABLE 122	ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)	126
TABLE 123	ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	126
TABLE 124	ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	126
TABLE 125	ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)	127
10.3.5	REST OF EUROPE	127
TABLE 126	ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)	127
TABLE 127	ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	128
TABLE 128	ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	128
TABLE 129	ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)	128
10.4	ASIA PACIFIC	129
TABLE 130	APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)	129
TABLE 131	APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)	129
TABLE 132	APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	130
TABLE 133	APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	130
TABLE 134	APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)	130
10.4.1	JAPAN	131
10.4.1.1	Japan dominates the APAC market for AI in drug discovery	131
TABLE 135	JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)	131
TABLE 136	JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	132
TABLE 137	JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	132
TABLE 138	JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)	132
10.4.2	CHINA	133
10.4.2.1	Growing CMO market and cross-industry collaborations are factors responsible for market growth in China	133
TABLE 139	CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)	133
TABLE 140	CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	133
TABLE 141	CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	134
TABLE 142	CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)	134
10.4.3	INDIA	134
10.4.3.1	Steady adoption of AI technologies will drive market growth in India	134
TABLE 143	INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)	135
TABLE 144	INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	135
TABLE 145	INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	135
TABLE 146	INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)	136
10.4.4	REST OF ASIA PACIFIC	136
TABLE 147	ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)	136
TABLE 148	ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	137
TABLE 149	ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	137
TABLE 150	ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)	137
10.5	REST OF THE WORLD	138
TABLE 151	ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020-2027 (USD MILLION)	138
TABLE 152	ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)	138
TABLE 153	ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)	139
TABLE 154	ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020-2027 (USD MILLION)	139
11	COMPETITIVE LANDSCAPE	140

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.1	OVERVIEW	140
11.2	KEY PLAYER STRATEGIES/RIGHT TO WIN	140
11.2.1	OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE AI IN DRUG DISCOVERY MARKET	140
11.3	MARKET RANKING ANALYSIS	141
TABLE 155	AI IN DRUG DISCOVERY MARKET RANKING ANALYSIS, BY KEY PLAYER, 2021	142
11.4	COMPETITIVE BENCHMARKING	143
TABLE 156	AI IN DRUG DISCOVERY MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS	143
TABLE 157	AI IN DRUG DISCOVERY MARKET: APPLICATION FOOTPRINT OF KEY PLAYERS	143
TABLE 158	AI IN DRUG DISCOVERY MARKET: REGIONAL FOOTPRINT OF KEY PLAYERS	144
11.5	COMPETITIVE LEADERSHIP MAPPING	144
11.5.1	STARS	144
11.5.2	EMERGING LEADERS	144
11.5.3	PERVASIVE PLAYERS	145
11.5.4	PARTICIPANTS	145
FIGURE 26	AI IN DRUG DISCOVERY MARKET: GLOBAL COMPANY EVALUATION MATRIX, 2021	145
11.6	COMPETITIVE LEADERSHIP MAPPING - START-UPS/SMES	146
11.6.1	PROGRESSIVE COMPANIES	146
11.6.2	STARTING BLOCKS	146
11.6.3	RESPONSIVE COMPANIES	146
11.6.4	DYNAMIC COMPANIES	146
FIGURE 27	AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021	147
11.7	COMPETITIVE SITUATIONS AND TRENDS	148
TABLE 159	PRODUCT LAUNCHES	148
TABLE 160	DEALS	148
12	COMPANY PROFILES	151
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *		
12.1	KEY PLAYERS	151
12.1.1	MICROSOFT	151
TABLE 161	MICROSOFT: BUSINESS OVERVIEW	151
FIGURE 28	MICROSOFT: COMPANY SNAPSHOT (2020)	152
TABLE 162	MICROSOFT: DEALS	153
12.1.2	NVIDIA	155
TABLE 163	NVIDIA: BUSINESS OVERVIEW	155
FIGURE 29	NVIDIA: COMPANY SNAPSHOT (2022)	156
TABLE 164	NVIDIA: EXPANSIONS	157
TABLE 165	NVIDIA: DEALS	157
12.1.3	EXSCIENTIA	158
TABLE 166	EXSCIENTIA: BUSINESS OVERVIEW	158
FIGURE 30	EXSCIENTIA: COMPANY SNAPSHOT (2021)	158
12.1.4	GOOGLE	162
TABLE 167	GOOGLE: BUSINESS OVERVIEW	162
FIGURE 31	GOOGLE: COMPANY SNAPSHOT (2021)	163
12.1.5	BENEVOLENTAI	165
TABLE 168	BENEVOLENTAI: BUSINESS OVERVIEW	165
12.1.6	NUMEDII, INC.	167
TABLE 169	NUMEDII: BUSINESS OVERVIEW	167

12.1.7	BERG, LLC	169
TABLE 170	BERG, LLC: BUSINESS OVERVIEW	169
12.1.8	ATOMWISE	171
TABLE 171	ATOMWISE: BUSINESS OVERVIEW	171
12.1.9	DEEP GENOMICS	173
TABLE 172	DEEP GENOMICS: BUSINESS OVERVIEW	173
12.1.10	INSILICO MEDICINE	175
TABLE 173	INSILICO MEDICINE: BUSINESS OVERVIEW	175
12.1.11	SCHRODINGER, INC.	177
TABLE 174	SCHRODINGER: BUSINESS OVERVIEW	177
FIGURE 32	SCHRODINGER: COMPANY SNAPSHOT (2021)	178
12.1.12	IBM	181
TABLE 175	IBM: BUSINESS OVERVIEW	181
FIGURE 33	IBM: COMPANY SNAPSHOT (2022)	182
TABLE 176	IBM: DEALS	183
TABLE 177	IBM: OTHER DEVELOPMENTS	183
12.2	OTHER PLAYERS	184
12.2.1	CYCLICA INC.	184
12.2.2	CLOUD PHARMACEUTICALS	184
12.2.3	BIOAGE	185
12.2.4	ENVISAGENICS	185
12.2.5	TWOXAR, INC. (ARIA PHARMACEUTICALS)	186
12.2.6	OWKIN, INC.	186
12.2.7	XTALPI, INC.	187
12.2.8	VERGE GENOMICS	187
12.2.9	IKTOS	188
12.2.10	EVAXION BIOTECH	188
12.2.11	STANDIGM	189
12.2.12	VALO HEALTH	190
12.2.13	BIOVISTA	190
12.2.14	BENCHSCI	191
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.		
?		
13	APPENDIX	192
13.1	DISCUSSION GUIDE	192
13.2	KNOWLEDGE STORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	195
13.3	AVAILABLE CUSTOMIZATIONS	197
13.4	RELATED REPORTS	197
13.5	AUTHOR DETAILS	198

**Artificial Intelligence (AI) in Drug Discovery Market by Offering (Software, Service),
Technology (Machine Learning, Deep Learning), Application (Cardiovascular,
Metabolic, Neurodegenerative), End User (Pharma, Biotech,CROs) - Global Forecasts
(2022 - 2027)**

Market Report | 2022-06-15 | 193 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-05-07
		Signature	<div></div>